Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

Carmela Giampa'; D Laurenti; S Anzilotti; G Bernardi; Fs Menniti; Fr Fusco

doi:10.1371/journal.pone.0013417

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

Carmela Giampa', D Laurenti, S Anzilotti, G Bernardi, Fs Menniti, Fr Fusco

Facoltà di Medicina e Chirurgia "A.Gemelli"

Risultato della ricerca: Contributo in rivista › Articolo in rivista

142 Citazioni (Scopus)

Abstract

Huntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons. To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized model system, the R6/2 mouse.

Lingua originale	English
pagine (da-a)	e13417-e13417
Rivista	PLoS One
Volume	5
DOI	https://doi.org/10.1371/journal.pone.0013417
Stato di pubblicazione	Pubblicato - 2010

Keywords

Animals
Corpus Striatum
Disease Models, Animal
Huntington Disease
Immunohistochemistry
Mice
Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Pyrazoles
Quinolines

Accesso al documento

10.1371/journal.pone.0013417

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{8786ffbade9743ddaa5118615eff8668,

title = "Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease",

abstract = "Huntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons. To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized model system, the R6/2 mouse.",

keywords = "Animals, Corpus Striatum, Disease Models, Animal, Huntington Disease, Immunohistochemistry, Mice, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Pyrazoles, Quinolines, Animals, Corpus Striatum, Disease Models, Animal, Huntington Disease, Immunohistochemistry, Mice, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Pyrazoles, Quinolines",

author = "Carmela Giampa' and D Laurenti and S Anzilotti and G Bernardi and Fs Menniti and Fr Fusco",

year = "2010",

doi = "10.1371/journal.pone.0013417",

language = "English",

volume = "5",

pages = "e13417--e13417",

journal = "PLoS One",

issn = "1932-6203",

publisher = "San Francisco, CA : Public Library of Science",

}

TY - JOUR

T1 - Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

AU - Giampa', Carmela

AU - Laurenti, D

AU - Anzilotti, S

AU - Bernardi, G

AU - Menniti, Fs

AU - Fusco, Fr

PY - 2010

Y1 - 2010

N2 - Huntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons. To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized model system, the R6/2 mouse.

AB - Huntington's disease is a devastating neurodegenerative condition for which there is no therapy to slow disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington's pathology is hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons. To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized model system, the R6/2 mouse.

KW - Animals

KW - Corpus Striatum

KW - Disease Models, Animal

KW - Huntington Disease

KW - Immunohistochemistry

KW - Mice

KW - Phosphodiesterase Inhibitors

KW - Phosphoric Diester Hydrolases

KW - Pyrazoles

KW - Quinolines

KW - Animals

KW - Corpus Striatum

KW - Disease Models, Animal

KW - Huntington Disease

KW - Immunohistochemistry

KW - Mice

KW - Phosphodiesterase Inhibitors

KW - Phosphoric Diester Hydrolases

KW - Pyrazoles

KW - Quinolines

UR - http://hdl.handle.net/10807/57490

U2 - 10.1371/journal.pone.0013417

DO - 10.1371/journal.pone.0013417

M3 - Article

VL - 5

SP - e13417-e13417

JO - PLoS One

JF - PLoS One

SN - 1932-6203

ER -

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo